Evidence map›Paper›PMID 42415718›Full record

ArticleEJHaem2026

Effectiveness and Safety of Prophylactic Low-Dose Emicizumab in Young Children With Hemophilia A: A Multicenter Retrospective Study.

Guichi Zhou, Liya He, Chunyan Wang, Yashuang Deng, Dong Peng, Zhaonan Liu, Sixi Liu, Xiaoying Fu, Ying Wang, Xiaoqin Feng

Abstract read
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guichi ZhouDepartment of Pediatric Hematology & Oncology Shenzhen Children's Hospital Shenzhen People's Republic of China.
Liya HeGuangzhou Women and Children's Medical Center Guangzhou Medical University Guangzhou People's Republic of China.
Chunyan WangDepartment of Pediatric Hematology & Oncology Shenzhen Children's Hospital Shenzhen People's Republic of China.
Yashuang DengDepartment of Pediatric Hematology & Oncology Shenzhen Children's Hospital Shenzhen People's Republic of China.
Dong PengDepartment of Laboratory Medicine Shenzhen Children's Hospital Shenzhen People's Republic of China.
Zhaonan LiuDepartment of Statistics University of Toronto Toronto Canada.
Sixi LiuDepartment of Pediatric Hematology & Oncology Shenzhen Children's Hospital Shenzhen People's Republic of China.
Xiaoying FuDepartment of Laboratory Medicine Shenzhen Children's Hospital Shenzhen People's Republic of China.
Ying WangDepartment of Pediatric Hematology & Oncology Shenzhen Children's Hospital Shenzhen People's Republic of China.
Xiaoqin FengDepartment of Pediatrics Nanfang Hospital Southern Medical University Guangzhou People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Real-world data on low-dose emicizumab in young children with hemophilia A are limited. Methods: This multicenter retrospective study included 26 children (median age: 2.2 years) receiving individualized low-dose emicizumab (2019-2025). Results: Over 48 months, the annualized bleeding rate decreased from 5.31 to 0.60 ( Conclusions: Low-dose emicizumab effectively reduces bleeding and improves quality of life, supporting its feasibility in resource-limited settings. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Indexed as

childrenemicizumabhemophilia Alow‐dose prophylaxisresource‐limited settings

Identifiers

PMID42415718
PMCPMC13338095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.